OTC obesity observed 1% current value growth to attain S$1 million sales in 2009. There were reports citing possible liver damage when consuming the OTC obesity drug Ecumenical during 2009 whereby consumers were advised to see a doctor if they encountered side effects such as fever, nausea or jaundice. This is thus likely to have a spillover effect on OTC obesity’s performance, which limited its overall growth.
The OTC Obesity Products in Singapore report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? - Get a detailed picture of the Consumer Health industry; - Pinpoint growth sectors and identify factors driving change; - Understand the competitive environment, the market’s major players and leading brands; - Use five-year forecasts to assess how the market is predicted to develop.
